Arming the Immune System to Kill Cancer

Our “off the shelf” stem cells deliver a viral payload that first kills cancer cells locally, and then supercharges the immune system to fight metastatic disease.

Learn More
A blue gloved hand holding a prescription bottle.

We are developing a new generation of targeted immunotherapies that  attack solid tumors, and then teach the immune system to hunt down cancer cells elsewhere in the body.

A person in blue gloves is filling a container with liquid.

Where does the “Calidi” name come from?

The Calidi name is derived from the spanish “caliente” meaning heat, which signifies that Calidi’s cancer treatment transforms immunologically “cold” tumors, which the immune system is unaware of,  becoming “hot” following Calidi’s treatment. The immune system is thus engaged, and attacks the primary tumor and also distant metastases.

Two men in white lab coats working in a lab.

Pioneering the Future

Calidi Biotherapeutics and City of Hope announce first patients dosed in a Phase 1 clinical trial, funded by the California Institute of Regenerative Medicine (CIRM), evaluating neural stem cells engineered to carry an oncolytic virus, CLD-101, in recurrent high-grade glioma patients.
Read More
Our Partners
A man in a suit and glasses sitting in front of a microphone.

Pioneering Progress

CEO of Calidi Biotherapeutics, Allan Camaisa, Visits Sully on Set of Big Biz TV to Discuss Recent Benchmarks in Advancing Pipeline for Cancer Cure.
Science

Discover the future of biotherapeutics with Calidi. Pioneering innovative solutions for solid tumors.

A person in a lab coat and purple gloves working on a machine.
Company Overview

Take a glimpse into Calidi's headquarters, based in San Diego, California, including members of our exceptional team. This video also highlights the latest updates on the company's Clinical Trials and path to becoming a publicly traded company.

A person in blue gloves is filling a container with liquid.
A tall building with a sign on the side of it.
Investors

Join us on our journey towards creating a world free from the threat of cancer.

A person in a lab with a large tank.

Discover the latest from our facility

In the Pipeline: Next-Generation Therapies

Explore Calidi Biotherapeutics' robust and evolving lineup of innovative immunotherapies, each designed with precision and a vision for a healthier future.

Learn More
A person in a lab coat working on a machine.

Meet the Visionaries Behind Calidi

Get to know the dedicated team at Calidi Biotherapeutics. A blend of experts and innovators, each member plays a pivotal role in our mission to redefine cancer treatment.

Learn More
A man and woman in lab coats looking at something.

Calidi Newsroom:
Stay Updated

Dive into the latest updates, research findings, and announcements from Calidi Biotherapeutics. Stay informed about our strides in the world of immunotherapy.

Learn More
A close up of a cell in the air.

Latest News

Press Release

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced registered direct offering, with a single institutional investor, for the issuance and sale of 3,325,000 shares of the Company’s common stock, and pre-funded warrants to purchase up to 2,728,000 shares of Common Stock. In a concurrent private placement, the Company issued and sold to the investor Series G common warrants to purchase up to an aggregate of 6,053,000 shares common stock.

March 31, 2025
Discover More
Discover More
Press Release

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2024 operating and financial results and reviewed recent business highlights.

March 31, 2025
Discover More
Discover More
Press Release

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement with a single institutional investor for the purchase and sale of 3,325,000 shares of the Company’s common stock at a per share purchase price of $0.65, and at the election of the investor, in lieu of the common stock, pre-funded warrants to purchase up to 2,728,000 shares of Common Stock at a price of $0.649 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant, in a registered direct offering.

March 28, 2025
Discover More
Discover More

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more